/ 
/ 
Ridaforolimus
From Wikipedia, the free encyclopedia
(Redirected from Deforolimus)
 |
|
| Systematic (IUPAC) name | |
|---|---|
| (1R,2R,4S)-4-[(2R)-2-[(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28Z,30S,32S,35R)-1,18-dihydroxy-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-2,3,10,14,20-pentaoxo-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraen-12-yl]propyl]-2-methoxycyclohexyl dimethylphosphinate | |
| Identifiers | |
| CAS number | 572924-54-0 |
| ATC code | none |
| PubChem | 11520894 |
| Chemical data | |
| Formula | C53H84NO14P |
| Therapeutic considerations | |
| Pregnancy cat. | ? |
| Legal status | |
Ridaforolimus (also known as AP23573 and MK-8669; formerly known as Deforolimus[1]) is an immunosuppressant currently undergoing research for the treatment of certain cancers. It is a small-molecule inhibitor of the mammalian target of rapamycin (mTOR). Blocking mTOR creates a starvation-like effect in cancer cells by interfering with cell growth, division, metabolism, and angiogenesis.
Ridaforolimus is being co-developed by Merck and ARIAD Pharmaceuticals. As of 2008[update], a phase III clinical trial of ridaforolimus in metastatic soft-tissue and bone sarcomas responsive to chemotherapy, SUCCEED (Sarcoma Multi-Center Clinical Evaluation of the Efficacy of Deforolimus), is recruiting patients.[2][3]
[edit] References
- ^ "ARIAD Reports First Quarter 2009 Development Progress and Financial Results- Ridaforolimus New USAN Name to Replace Deforolimus". ARIAD Pharmaceuticals. 2009. http://phx.corporate-ir.net/phoenix.zhtml?c=118422&p=irol-newsArticle&ID=1285640&highlight=. Retrieved 2009-05-07.
- ^ "SUCCEED: Landmark Global Phase 3 Trial Now Enrolling!". ARIAD Pharmaceuticals. 2008. http://www.ariad.com/wt/page/succeed. Retrieved 2008-04-18.
- ^ Deforolimus (AP23573) in Treatment of Sarcoma - SUCCEED (Sarcoma Multi-Center Clinical Evaluation of the Efficacy of Deforolimus) Study. ClinicalTrials.gov (2008-03-07). Retrieved on 2008-04-18.
[edit] External links
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |